Zydus Lifesciences Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 21.2%)
- Efficient capital deployment (ROCE 21.1%)
- Attractively valued vs sector (P/E 23x vs industry 54.7x)
- Low debt relative to equity (D/E 0.5x)
Concerns
Today's Price Action
The stock is trading at ₹1,120 with flat intraday movement. Volume today matches the 20‑day average of 5,16,679 shares, indicating a neutral participation level and no immediate shift in market interest.
Valuation Snapshot
Zydus Lifesciences Ltd. carries a forward P/E of 24.4, while the broader healthcare sector shows a zero‑P/E baseline, reflecting the absence of comparable peers with positive earnings. The company’s return on equity stands at 21.2%, signalling a robust profit generation capability relative to its equity base.
Key Levels to Watch
The current price is positioned near the upper end of the 52‑week range (₹836 – ₹1,206), roughly 7 % below the year‑high. Open‑interest data on nearby strike prices suggest a modest resistance cluster around ₹1,200, while support appears near the ₹1,000 mark.
Chart Pattern
On the daily timeframe, the last ten sessions have produced a bearish engulfing candle three days ago, a bullish harami four days ago, and an evening star five days ago. These formations reflect short‑term indecision and potential exhaustion of prior trends without implying a definitive direction.
Data Summary
Key metrics highlight a flat‑priced share at ₹1,120, a P/E of 24.4, and an ROE of 21.2%. The stock’s 52‑week high sits at ₹1,206, and its trading volume aligns exactly with the 20‑day average of 5,16,679 shares.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
| LUPIN Lupin Limited | ₹2,110 | ₹96K Cr | 16.2 | 4.3 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ZYDUSLIFE · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.98% | 74.98% | 74.98% | 74.98% | 74.98% | 75.00% |
| FII | 4.99% | 5.72% | 5.59% | 7.52% | 7.53% | 7.31% |
| DII | 12.96% | 12.55% | 12.56% | 10.59% | 10.61% | 10.95% |
| Public | 6.99% | 6.66% | 6.81% | 6.85% | 6.85% | 6.69% |
| Govt | 0.07% | 0.07% | 0.07% | 0.05% | 0.05% | 0.05% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Re 1 Per Share
Buy Back
To consider buyback for equity shares
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 11 Per Share
Dividend - Rs 3 Per Share
Buy Back
Dividend - Rs 6 Per Share
Latest News
All newsZydus Lifesciences reports Q1FY26 financial results
*Zydus Lifesciences reports Q1FY26 financial results*. The company has submitted its financial results for the quarter ended June 30, 2026. Key metrics include revenue of **₹2,147 crore** and net profit of **₹237 crore**, showing growth year-on-year. Results reflect strong performance in both domestic and international markets. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Zydus reports positive Phase II(b) trial results for Saroglitazar Mg
*Zydus reports positive Phase II(b) trial results for Saroglitazar Mg*. Zydus Lifesciences announced positive topline results from its EVIDENCES-X Phase II(b) trial for Saroglitazar Mg in MASH patients. The drug showed **improvement in liver histology** and metabolic parameters, boosting near-term pipeline hopes. This success enhances regulatory prospects and may drive investor sentiment positively. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ClinicalTrial
Zydus wins USFDA approval for Ascorbic Acid Injection
*Zydus wins USFDA approval for Ascorbic Acid Injection*. The company announced final approval for its injectable vitamin C product with **180-day CGT exclusivity**, boosting its US generics portfolio. This exclusivity may delay rival approvals, enhancing near-term revenue potential. The development strengthens Zydus’s position in the competitive USFDA-regulated market. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA
Zydus launches India's first once-daily nebulised LAMA for COPD
*Zydus launches India's first once-daily nebulised LAMA for COPD*. The company introduced REVAHALE, a novel treatment for chronic obstructive pulmonary disease (COPD), marking a significant product launch in the respiratory therapeutics space. This positions Zydus as a pioneer in nebuliser-based maintenance therapy in India. The launch could drive future revenue growth and market share gains. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Zydus gets USFDA nod for injectable drug with 180-day exclusivity
*Zydus gets USFDA nod for injectable drug with 180-day exclusivity*. Zydus Lifesciences announced final approval from the USFDA for Indocyanine Green for Injection, granting it **180-day** Competitive Generic Therapy (CGT) exclusivity. This approval allows Zydus to launch the product ahead of competitors, potentially capturing early market share. The exclusivity period is expected to provide a revenue boost in the near term. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA
Zydus ties up with Apollo to expand cancer test access
*Zydus ties up with Apollo to expand cancer test access* — Zydus Lifesciences has signed an MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test across India. The collaboration aims to enhance early cancer screening in tier-2 and tier-3 cities. The test is currently available in **15 cities** and plans to scale to **50 cities** by 2027. 📊 *STOCKS:* ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Partnership
Zydus Lifesciences announces general updates via NSE filing
*Zydus Lifesciences announces general updates via NSE filing.* The company filed routine corporate updates with the exchange, though no specific financial or operational details were disclosed. Such filings typically include administrative or compliance-related information. Investors await further clarity on material developments. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Zydus Lifesciences announces general corporate updates.
*Zydus Lifesciences announces general corporate updates.* The filing provides routine information without disclosing specific financials or strategic shifts. Details remain broad, citing standard regulatory compliance. Investors await further clarity on operational developments. 📊 *STOCKS:* ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
Zydus wins US FDA approval for injectable vitamin C with exclusivity
*Zydus wins US FDA approval for injectable vitamin C with exclusivity.* The company received final approval for Ascorbic Acid Injection, granting it **180-day CGT exclusivity**. This allows Zydus to launch the product before competitors, potentially capturing early market share. The approval strengthens its US generics portfolio. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval
Zydus gets USFDA approval for injectable vitamin C
*Zydus gets USFDA approval for injectable vitamin C* — Zydus Lifesciences has received approval from the USFDA for its Abbreviated New Drug Application (ANDA) for ascorbic acid (vitamin C) injection, 1g/5mL. The product is a generic version of Fresenius Kabi’s VITAL-5. This approval expands Zydus’s portfolio in the US market, reinforcing its injectables segment. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6.9K Cr 12.1% | ₹6.1K Cr 6.9% | ₹6.6K Cr 0.7% | ₹6.5K Cr 23.9% | ₹5.3K Cr 0.6% | ₹5.2K Cr 15.6% | ₹6.2K Cr 12.2% | ₹5.5K Cr |
| Op. Profit | ₹1.8K Cr 9.9% | ₹2.0K Cr 3.4% | ₹2.1K Cr 1.8% | ₹2.1K Cr 53.2% | ₹1.4K Cr 5.0% | ₹1.5K Cr 29.9% | ₹2.1K Cr 27.9% | ₹1.6K Cr |
| OPM | 26.0% 21.2% | 33.0% 3.1% | 32.0% 3.0% | 33.0% 26.9% | 26.0% 7.1% | 28.0% 17.6% | 34.0% 17.2% | 29.0% |
| Net Profit | ₹1.0K Cr 17.4% | ₹1.2K Cr 18.5% | ₹1.5K Cr 22.3% | ₹1.2K Cr 21.2% | ₹1.0K Cr 11.5% | ₹920 Cr 37.9% | ₹1.5K Cr 18.9% | ₹1.2K Cr |
| EPS (₹) | 10.36 17.2% | 12.51 14.2% | 14.58 25.3% | 11.64 14.5% | 10.17 12.3% | 9.06 35.8% | 14.11 20.1% | 11.75 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹27.1K Cr 16.8% | ₹23.2K Cr 18.9% | ₹19.5K Cr 13.4% | ₹17.2K Cr 12.9% | ₹15.3K Cr 1.1% | ₹15.1K Cr 6.0% | ₹14.3K Cr 8.3% | ₹13.2K Cr 10.6% | ₹11.9K Cr 27.0% | ₹9.4K Cr |
| Expenses | ₹18.7K Cr 15.4% | ₹16.2K Cr 14.3% | ₹14.2K Cr 5.9% | ₹13.4K Cr 12.2% | ₹11.9K Cr 1.4% | ₹11.8K Cr 2.6% | ₹11.5K Cr 12.6% | ₹10.2K Cr 12.1% | ₹9.1K Cr 21.4% | ₹7.5K Cr |
| Op. Profit | ₹8.5K Cr 20.1% | ₹7.1K Cr 31.1% | ₹5.4K Cr 39.5% | ₹3.9K Cr 15.5% | ₹3.3K Cr 0.1% | ₹3.3K Cr 19.5% | ₹2.8K Cr 6.5% | ₹3.0K Cr 5.7% | ₹2.8K Cr 48.8% | ₹1.9K Cr |
| OPM | 31.0% 3.3% | 30.0% 7.1% | 28.0% 27.3% | 22.0% 0.0% | 22.0% 0.0% | 22.0% 10.0% | 20.0% 13.0% | 23.0% 4.2% | 24.0% 20.0% | 20.0% |
| Other Income | ₹-7 Cr 114.0% | ₹50 Cr 82.9% | ₹293 Cr 169.4% | ₹-422 Cr 116.4% | ₹2.6K Cr 1609.4% | ₹-171 Cr 35.2% | ₹-264 Cr 244.3% | ₹183 Cr 64.9% | ₹111 Cr 12.6% | ₹127 Cr |
| Interest | ₹439 Cr 164.5% | ₹166 Cr 104.9% | ₹81 Cr 37.7% | ₹130 Cr 2.4% | ₹127 Cr 22.6% | ₹164 Cr 52.0% | ₹342 Cr 76.3% | ₹194 Cr 113.2% | ₹91 Cr 102.2% | ₹45 Cr |
| Depreciation | ₹1.4K Cr 53.7% | ₹916 Cr 19.9% | ₹764 Cr 5.7% | ₹723 Cr 1.4% | ₹713 Cr 1.7% | ₹725 Cr 4.2% | ₹696 Cr 16.2% | ₹599 Cr 11.1% | ₹539 Cr 44.5% | ₹373 Cr |
| PBT | ₹6.6K Cr 9.9% | ₹6.0K Cr 24.7% | ₹4.8K Cr 86.9% | ₹2.6K Cr 49.2% | ₹5.1K Cr 122.5% | ₹2.3K Cr 52.8% | ₹1.5K Cr 37.2% | ₹2.4K Cr 3.0% | ₹2.3K Cr 43.4% | ₹1.6K Cr |
| Tax % | 24.0% 4.3% | 23.0% 15.0% | 20.0% 13.0% | 23.0% 130.0% | 10.0% 66.7% | 6.0% 71.4% | 21.0% 4.5% | 22.0% 8.3% | 24.0% 200.0% | 8.0% |
| Net Profit | ₹5.1K Cr 9.7% | ₹4.7K Cr 17.6% | ₹4.0K Cr 89.9% | ₹2.1K Cr 54.7% | ₹4.6K Cr 111.4% | ₹2.2K Cr 81.5% | ₹1.2K Cr 36.6% | ₹1.9K Cr 4.9% | ₹1.8K Cr 19.3% | ₹1.5K Cr |
| EPS (₹) | 50.09 11.4% | 44.97 17.2% | 38.36 98.0% | 19.37 55.8% | 43.83 110.3% | 20.84 81.4% | 11.49 36.4% | 18.06 4.1% | 17.35 19.4% | 14.53 |
| Div Payout | 2.0% 91.7% | 24.0% 200.0% | 8.0% 74.2% | 31.0% 416.7% | 6.0% 64.7% | 17.0% 43.3% | 30.0% 57.9% | 19.0% 5.0% | 20.0% 9.1% | 22.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹101 Cr 0.0% | ₹101 Cr 0.0% | ₹101 Cr 0.0% | ₹101 Cr 1.0% | ₹102 Cr 0.0% | ₹102 Cr 0.0% | ₹102 Cr 0.0% | ₹102 Cr 0.0% | ₹102 Cr 0.0% | ₹102 Cr |
| Reserves | ₹25.2K Cr 5.7% | ₹23.9K Cr 20.9% | ₹19.7K Cr 13.3% | ₹17.4K Cr 3.1% | ₹16.9K Cr 31.1% | ₹12.9K Cr 25.5% | ₹10.3K Cr 0.1% | ₹10.3K Cr 19.0% | ₹8.6K Cr 26.0% | ₹6.9K Cr |
| Borrowings | ₹9.6K Cr 199.9% | ₹3.2K Cr 299.6% | ₹804 Cr 32.7% | ₹1.2K Cr 71.7% | ₹4.2K Cr 7.9% | ₹4.6K Cr 42.6% | ₹8.0K Cr 1.1% | ₹7.9K Cr 46.1% | ₹5.4K Cr 3.8% | ₹5.2K Cr |
| Other Liabilities | ₹12.0K Cr 25.6% | ₹9.5K Cr 16.1% | ₹8.2K Cr 19.7% | ₹6.9K Cr 6.7% | ₹6.4K Cr 3.7% | ₹6.2K Cr 21.0% | ₹5.1K Cr 3.4% | ₹4.9K Cr 36.2% | ₹3.6K Cr 23.7% | ₹2.9K Cr |
| Total Liabilities | ₹46.9K Cr 27.8% | ₹36.7K Cr 27.2% | ₹28.8K Cr 12.8% | ₹25.6K Cr 7.5% | ₹27.6K Cr 16.3% | ₹23.8K Cr 1.2% | ₹23.5K Cr 1.1% | ₹23.2K Cr 30.6% | ₹17.8K Cr 17.7% | ₹15.1K Cr |
Assets | ||||||||||
| Fixed Assets | ₹23.1K Cr 75.6% | ₹13.1K Cr 6.2% | ₹12.4K Cr 7.4% | ₹11.5K Cr 6.0% | ₹12.3K Cr 1.0% | ₹12.1K Cr 0.8% | ₹12.2K Cr 0.5% | ₹12.2K Cr 87.6% | ₹6.5K Cr 12.6% | ₹5.8K Cr |
| CWIP | ₹1.2K Cr 55.8% | ₹2.7K Cr 11.1% | ₹2.4K Cr 101.7% | ₹1.2K Cr 81.7% | ₹661 Cr 15.6% | ₹783 Cr 5.5% | ₹742 Cr 11.4% | ₹837 Cr 45.2% | ₹1.5K Cr 1.0% | ₹1.5K Cr |
| Investments | ₹5.9K Cr 8.3% | ₹6.4K Cr 425.6% | ₹1.2K Cr 21.1% | ₹1.5K Cr 53.0% | ₹3.3K Cr 296.1% | ₹830 Cr 8.5% | ₹765 Cr 13.5% | ₹674 Cr 9.7% | ₹746 Cr 71.5% | ₹435 Cr |
| Other Assets | ₹16.8K Cr 16.0% | ₹14.5K Cr 12.7% | ₹12.8K Cr 13.5% | ₹11.3K Cr 1.3% | ₹11.4K Cr 14.2% | ₹10.0K Cr 2.9% | ₹9.7K Cr 1.9% | ₹9.6K Cr 5.8% | ₹9.0K Cr 22.5% | ₹7.4K Cr |
| Total Assets | ₹46.9K Cr 27.8% | ₹36.7K Cr 27.2% | ₹28.8K Cr 12.8% | ₹25.6K Cr 7.5% | ₹27.6K Cr 16.3% | ₹23.8K Cr 1.2% | ₹23.5K Cr 1.1% | ₹23.2K Cr 30.6% | ₹17.8K Cr 17.7% | ₹15.1K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹6.8K Cr 110.1% | ₹3.2K Cr 20.0% | ₹2.7K Cr 27.8% | ₹2.1K Cr 36.1% | ₹3.3K Cr 31.5% | ₹2.5K Cr 95.4% | ₹1.3K Cr 39.5% | ₹919 Cr 30.0% | ₹1.3K Cr 30.7% | ₹1.9K Cr |
| Investing CF | ₹-8.4K Cr 460.5% | ₹-1.5K Cr 226.7% | ₹1.2K Cr 3.6% | ₹1.1K Cr 236.2% | ₹-835 Cr 17.5% | ₹-1.0K Cr 74.6% | ₹-4.0K Cr 308.3% | ₹-974 Cr 66.1% | ₹-2.9K Cr 234.0% | ₹-860 Cr |
| Financing CF | ₹2.0K Cr 210.2% | ₹-1.8K Cr 58.9% | ₹-4.4K Cr 406.9% | ₹-868 Cr 65.9% | ₹-2.5K Cr 133.0% | ₹-1.1K Cr 158.0% | ₹1.9K Cr 3525.0% | ₹52 Cr 97.8% | ₹2.3K Cr 347.7% | ₹-935 Cr |
| Net Cash Flow | ₹414 Cr 652.0% | ₹-75 Cr 86.0% | ₹-534 Cr 122.5% | ₹2.4K Cr 2736.7% | ₹-90 Cr 122.6% | ₹399 Cr 149.2% | ₹-811 Cr 26933.3% | ₹-3 Cr 100.4% | ₹756 Cr 663.6% | ₹99 Cr |
| Free Cash Flow | ₹5.1K Cr 119.1% | ₹2.3K Cr 38.2% | ₹1.7K Cr 61.6% | ₹1.1K Cr 57.1% | ₹2.4K Cr 51.3% | ₹1.6K Cr 585.2% | ₹236 Cr 303.4% | ₹-116 Cr 92.9% | ₹-1.6K Cr 273.4% | ₹936 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64d 34.0% | 97d 3.2% | 94d 17.5% | 80d 5.3% | 76d 19.1% | 94d 14.5% | 110d 12.2% | 98d 10.1% | 89d 30.9% | 68d |
| Inventory Days | 227d 12.4% | 202d 2.5% | 197d 19.6% | 245d 7.9% | 227d 9.7% | 207d 0.5% | 208d 1.4% | 211d 9.3% | 193d 22.2% | 158d |
| Days Payable | 131d 4.8% | 125d 1.6% | 123d 12.8% | 141d 9.0% | 155d 2.6% | 151d 1.3% | 149d 10.8% | 167d 1.2% | 165d 7.1% | 154d |
| Cash Conv. Cycle | 160d 8.6% | 175d 4.2% | 168d 8.7% | 184d 24.3% | 148d 1.3% | 150d 11.2% | 169d 19.0% | 142d 22.4% | 116d 63.4% | 71d |
| Working Capital Days | 3d 96.6% | 88d 25.7% | 70d 268.4% | 19d 416.7% | -6d 68.4% | -19d 290.0% | 10d 41.2% | 17d 150.0% | -34d 3300.0% | -1d |
| ROCE | 24.0% 9.1% | 22.0% 46.7% | 15.0% 15.4% | 13.0% 7.1% | 14.0% 27.3% | 11.0% 26.7% | 15.0% 16.7% | 18.0% 12.5% | 16.0% 42.9% | 28.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Zydus Lifesciences Limited
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
HealthcarePharmaceuticals & Biotechnology